Austrálie - angličtina - APVMA (Australian Pesticides and Veterinary Medicines Authority)

international animal health products pty ltd - glutaraldehyde; quaternary ammonium compound - aqueous concentrate - glutaraldehyde aldehyde active 151.0 g/l; quaternary ammonium compound ammonium-quaternary active 104.0 g/l - disinfectant - broiler & other deep litter sheds | dairy or milking shed | general disinfection (walls, stalls,etc) | general disinfection-pigp - bacteria | fungus | general disinfection | virus | antiviral agent | aviaries | catteries | detergent | feeding utensils | flesh wounds | floor | fungal leaf spots | fungi | fungus diseases | germicidal detergent | kennel | leaf spot diseases | leaf spots | mastitis | mould growth | poultry cages | protozoans | stables | toilets (not septic) | walls

Austrálie - angličtina - APVMA (Australian Pesticides and Veterinary Medicines Authority)

qpharma pty ltd - povidone-iodine; iodophor - topical cream, ointment, paste, gel, lotion - povidone-iodine emulsifiers & surfactants active 15.0 g/l; iodophor mineral-iodine active 6.0 g/l - dermatological preps.

Austrálie - angličtina - APVMA (Australian Pesticides and Veterinary Medicines Authority)

boehringer ingelheim animal health australia pty. ltd. - carbomer; mycoplasma hyopneumoniae - inactivated antigen - misc. vaccines or anti sera - carbomer ungrouped active 1.0 mg; mycoplasma hyopneumoniae - inactivated antigen vaccine-general active 1.0 rp - immunotherapy

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

besins healthcare australia pty ltd - progesterone, quantity: 200 mg - pessary, shell - excipient ingredients: glycerol; lecithin; titanium dioxide; gelatin; purified water; sunflower oil - luteal phase support ? luteal support of assisted reproductive technology (art) cycles,support during pregnancy ? prevention of preterm birth in women with singleton pregnancy who have a short cervix (midtrimester sonographic cervix less than or equal to 25 mm) and/or a history of spontaneous preterm birth. ? treatment of unexplained threatened miscarriage in women with bleeding in the current pregnancy and a history of at least three or more previous miscarriages. use in women with less than three miscarriages may be warranted in those with reduced chances of future pregnancy such as those undergoing ivf treatment with limited viable egg and/or embryo availability or advanced fertility age. however, the benefit of treatment in clinical trials was limited to women with three or more miscarriages. (see section 5 pharmacological properties; clinical trials; threatened unexplained miscarriage)

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

besins healthcare australia pty ltd - progesterone, quantity: 200 mg - capsule, soft - excipient ingredients: glycerol; lecithin; titanium dioxide; gelatin; purified water; sunflower oil - prometrium 100 mg and 200 mg, soft capsules are indicated for:,treatment of menstrual irregularities,- in women with menstrual abnormalities or secondary amenorrhoea due to normogonadotrophic amenorrhoea (see dosage and administration),hormone replacement therapy,- hormone replacement therapy ? adjunctive use with an oestrogen in postmenopausal women with an intact uterus

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

besins healthcare australia pty ltd - progesterone, quantity: 100 mg - capsule, soft - excipient ingredients: glycerol; lecithin; titanium dioxide; gelatin; purified water; sunflower oil - prometrium 100 mg and 200 mg, soft capsules are indicated for:,treatment of menstrual irregularities,- in women with menstrual abnormalities or secondary amenorrhoea due to normogonadotrophic amenorrhoea (see dosage and administration),hormone replacement therapy,- hormone replacement therapy ? adjunctive use with an oestrogen in postmenopausal women with an intact uterus

Spojené státy - angličtina - NLM (National Library of Medicine)

taro pharmaceuticals u.s.a., inc. - nortriptyline hydrochloride (unii: 00fn6ih15d) (nortriptyline - unii:bl03sy4lxb) - solution - 10 mg in 5 ml - nortriptyline hydrochloride is indicated for the relief of symptoms of depression. endogenous depressions are more likely to be alleviated than are other depressive states. the concurrent use of nortriptyline hydrochloride or other tricyclic antidepressants with a monoamine oxidase (mao) inhibitor is contraindicated. hyperpyretic crises, severe convulsions, and fatalities have occurred when similar tricyclic antidepressants were used in such combinations. it is advisable to discontinue the mao inhibitor at least 2 weeks before treatment with nortriptyline hydrochloride is to be started. patients hypersensitive to nortriptyline hydrochloride should not be given the drug. cross-sensitivity between nortriptyline hydrochloride and other dibenzazepines is a possibility. nortriptyline hydrochloride is contraindicated during the acute recovery period after myocardial infarction.

Spojené státy - angličtina - NLM (National Library of Medicine)

a-s medication solutions - nortriptyline hydrochloride (unii: 00fn6ih15d) (nortriptyline - unii:bl03sy4lxb) - nortriptyline 25 mg - nortriptyline hydrochloride is indicated for the relief of symptoms of depression. endogenous depressions are more likely to be alleviated than are other depressive states. the use of maois intended to treat psychiatric disorders with nortriptyline hydrochloride or within 14 days of stopping treatment with nortriptyline hydrochloride is contraindicated because of an increased risk of serotonin syndrome. the use of nortriptyline hydrochloride within 14 days of stopping an maoi intended to treat psychiatric disorders is also contraindicated (see  warnings and dosage and administration ). starting nortriptyline hydrochloride in a patient who is being treated with maois such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin syndrome (see  warnings  and  dosage and administration ). cross-sensitivity between nortriptyline hydrochloride and other dibenzazepines is a possibility. nortriptyline hydrochloride is contraindicated during the acute recovery period after myocardial infarction.

Spojené státy - angličtina - NLM (National Library of Medicine)

unit dose services - nortriptyline hydrochloride (unii: 00fn6ih15d) (nortriptyline - unii:bl03sy4lxb) - nortriptyline 25 mg - nortriptyline hydrochloride is indicated for the relief of symptoms of depression. endogenous depressions are more likely to be alleviated than are other depressive states. the use of maois intended to treat psychiatric disorders with nortriptyline hydrochloride or within 14 days of stopping treatment with nortriptyline hydrochloride is contraindicated because of an increased risk of serotonin syndrome. the use of nortriptyline hydrochloride within 14 days of stopping an maoi intended to treat psychiatric disorders is also contraindicated (see warnings and dosage and administration ). starting nortriptyline hydrochloride in a patient who is being treated with maois such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin syndrome (see warnings and dosage and administration ). cross-sensitivity between nortriptyline hydrochloride and other dibenzazepines is a possibility. nortriptyline hydrochloride is contraindicated during the acute recovery period

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

besins healthcare australia pty ltd - estradiol hemihydrate, quantity: 0.06 % w/w (equivalent: estradiol, qty 0.06 % w/w) - gel - excipient ingredients: carbomer 980; trolamine; ethanol; purified water - - hormone replacement therapy (hrt) for estrogen deficiency symptoms in postmenopausal women.,- prevention of osteoporosis in postmenopausal women at high risk of future fractures who are intolerant of, or contraindicated for, other medicinal products approved for the prevention of osteoporosis. (see also section 4.4 special warnings and precautions for use),the experience treating women older than 65 years is limited. the lowest effective dose should be used for the shortest duration (see sections 4.2 dose and method of administration and 4.4 special warnings and precautions for use).